About the Neuroblastoma Program
The Neuroblastoma Program at Texas Children’s Hospital has grown to become one of the top referral centers in the country for treating this condition.
Our multidisciplinary team includes dedicated physicians, nurses and research coordinators who focus solely on neuroblastoma.
We work closely with our Surgical Oncology Group (all of whom are neuroblastoma researchers), the Solid Tumor Program, the Pathology Section, the Center for Cell and Gene Therapy (Bone Marrow Transplant and Immunotherapy research group) and a wealth of social support services provided by Texas Children’s Hospital.
Treatment and Evaluation
Neuroblastoma is one of the most common solid tumors in children, and approximately 700 patients are diagnosed each year in the United States. We care for patients of all ages diagnosed with neuroblastic lesions, from benign masses to highly aggressive, malignant tumors.
Our program is focused not only on methods to improve our current care platform, but also to incorporate additional non-toxic treatment options to improve cure rates. Our comprehensive treatment options include surgery, radiation therapy, high-dose chemotherapy with stem cell rescue, and immunotherapy with antibody, T cells and/or vaccines.
Texas Children’s Cancer Center offers MIBG therapy for patients with high-risk relapsed or refractory neuroblastoma. In keeping with our mission to provide personalized, comprehensive services as well as family-centered care for every patient, I-131MIBG treatment is offered to patients in a two-room suite that allows a parent to stay close to their child throughout the length of treatment. A viewing window separates the two rooms. In addition to an intercom system between the rooms, both patient and parent will be provided with iPads for communication. The patient room is equipped to manage safe delivery of therapy to the patient as well as protect staff and parents from unwanted radiation when entering the room for short periods of time. The parent room is fully equipped with a bed, couch, and full private bathroom. Learn more about MIBG therapy.
Neuroblastoma remains a therapeutic challenge and there is an urgent need for additional research to develop more effective and less toxic treatment options for children with this disease.
Clinically, our program offers novel treatment options including Investigational New Drug (IND) trials, Children’s Oncology Group (COG) studies and local pilot clinical studies. Over the last decade, our translational program has become nationally recognized for the development and use of immunotherapy in patients with relapsed or refractory disease. We recently completed and published the largest trial using chimeric antigen receptor T cells designed specifically for children with neuroblastoma.
We recognize that standard treatment options will not work for all children. Therefore, we are actively investigating new sequencing and genomic approaches to better characterize neuroblastoma tumors.
Donate to the Neuroblastoma Program
Donations to support the Neuroblastoma Program may be made online. Please make sure to specify under ‘Comments’ that the donation is for the Neuroblastoma Program.